Intercept Pharmaceuticals, a drug maker racing to find a cure for a little-understood liver disease, is in advanced discussions to take space at 55 Hudson Yards, sources close to the negotiations told The Real Deal. The firm, which went public in 2012, is looking to lease somewhere between 90,000 and 150,000 square feet at the 51-story property, a joint venture between Related Companies, Oxford Properties and Mitsui Fudosan, sources said.